China’s rapidly advancing generic drug industry has presented JlABO with significant growth opportunities. In response, we have overcome technical bottlenecks in complex injectable formulations, achieving breakthroughs that enhance the availability of essential medicines—particularly those in short supply—thereby better meeting the needs of both domestic and global patients.